India's self-medication rate exceeds 50% in urban areas, according to WHO-SEARO data and multiple Indian pharmacological studies, making over-the-counter drug misuse a silent public health crisis. The habit fuels antibiotic resistance, masks serious illness, and costs lives — yet India's regulatory framework still treats the corner pharmacy as a retail counter, not a clinical gatekeep.
A man walks into a pharmacy in Hyderabad's Ameerpet. He has had a cough for nine days. He does not want a doctor; he wants the blue syrup that worked last monsoon. The pharmacist — technically not authorised to prescribe — sells it without a question. Multiplied across six hundred thousand pharmacies and 1.4 billion people, that transaction is the most consequential medical act in India. And nobody regulates it.
According to a widely cited 2023 study published in the Indian Journal of Pharmacology, self-medication prevalence in urban India ranges between 50% and 73%, depending on the city and the study sample. The World Health Organization's South-East Asia Regional Office (WHO-SEARO) has flagged India repeatedly as a high-burden self-medication zone, noting that the practice is a primary driver of antimicrobial resistance — a threat the WHO now ranks alongside climate change in global health risk.
The numbers underneath that habit are staggering. India's OTC pharmaceutical market was valued at approximately ₹12,000 crore in 2024–25, according to estimates from the Indian Pharmaceutical Alliance and pharma-sector analysts tracked by IQVIA. That figure does not include the shadow economy of Schedule H drugs — technically prescription-only — sold over the counter in flagrant violation of the Drugs and Cosmetics Act, 1940. A 2022 survey by the Indian Medical Association found that nearly 46% of antibiotics dispensed at retail pharmacies across five metro cities were sold without a valid prescription.
This is the architecture of a public health disaster hiding in plain sight. And the monsoon, now firmly here, is its annual accelerant.
The Monsoon Multiplier
Every Indian monsoon triggers a predictable spike in respiratory infections, waterborne gastrointestinal illness, and dengue-spectrum fevers. What public health officials at the National Centre for Disease Control (NCDC) note with growing alarm is that these seasonal surges now arrive pre-medicated. Patients reach hospitals not at symptom onset but after days — sometimes weeks — of self-administered paracetamol-antibiotic-antacid cocktails that have masked fevers, suppressed cough reflexes that should have prompted chest X-rays, and wiped out gut flora that was the body's first defence.
The clinical cost is measurable. Drug-induced liver injury (DILI), driven overwhelmingly by unsupervised paracetamol and traditional-medicine combinations, accounted for roughly 10% of acute liver failure cases at major tertiary centres, according to data published in the Journal of Clinical and Experimental Hepatology (an Indian gastroenterology journal). That one statistic should end every casual conversation about "just taking a Crocin."
Antibiotic resistance, meanwhile, has crossed from clinical concern into civilisational threat. India is the world's largest consumer of antibiotics, per a landmark study in The Lancet Infectious Diseases, and the Indian Council of Medical Research's (ICMR) annual resistance surveillance data shows that resistance rates for common gram-negative bacteria now exceed 70% for some first-line antibiotics in Indian hospital isolates. Every incomplete course bought over the counter at that Ameerpet pharmacy feeds the machine.
Why the Pharmacy Counter Became the Doctor's Clinic
The roots are structural, not merely cultural. India's doctor-to-population ratio — roughly 1:1,000 according to the National Health Profile 2023, published by the Central Bureau of Health Intelligence — technically meets the WHO minimum, but the distribution is grotesquely uneven: urban India has roughly four times the physician density of rural India. A specialist consultation in a private hospital can cost ₹500–₹1,500; the pharmacist's advice is free. The economic logic is merciless, and it is the poor who pay the clinical price.
Add to this an advertising ecosystem that actively encourages the behaviour. India's consumer healthcare advertising — for pain-relief gels, cough syrups, digestive aids, immunity boosters — is a multi-thousand-crore annual expenditure, largely unregulated in its claims. The Advertising Standards Council of India (ASCI) periodically flags violations, but enforcement is complaint-driven and retrospective, arriving long after the ad has done its work on consumer behaviour.
Online pharmacy platforms, which boomed during the COVID-19 pandemic and continue to expand rapidly through 2025–2026, introduced a new wrinkle: prescription-upload requirements that are easily bypassed, auto-refill features that normalise repeat purchases, and algorithm-driven recommendations ("customers also bought...") that function as de facto medical advice.
The Regulatory Gap Nobody Wants to Close
India's drug scheduling system — Schedule H (prescription required), Schedule H1 (prescription required, record maintained), Schedule X (strict control) — exists on paper and is honoured mostly in the breach. The Central Drugs Standard Control Organisation (CDSCO) and state drug controllers lack the inspection bandwidth to police six hundred thousand-plus pharmacies. Pharmacists themselves, in many establishments, are absent or nominal — the person behind the counter is often an unlicensed shop assistant.
India Herald's read of the deeper structural failure is this: the Indian state has built a healthcare access model that implicitly relies on the pharmacy counter as the first point of care for the majority, while simultaneously pretending in law that the pharmacy is merely a dispensing point. The gap between the legal fiction and the lived reality is where the damage happens — and closing it would require either massively scaling primary healthcare access (expensive, slow) or honestly regulating the pharmacy counter as a clinical-advice point with trained, accountable personnel (politically difficult, industry-opposed). Neither is happening at pace.
The Drugs and Cosmetics (Amendment) Bill discussions that have recurred in Parliamentary sessions through 2024–2026, according to PRS Legislative Research tracking, have touched on prescription enforcement and online pharmacy regulation, but comprehensive reform remains pending — caught between a powerful pharmaceutical lobby, state-level implementation resistance, and the sheer inertia of a system that technically "works" as long as you do not count the bodies.
What the Careful Reader Should Actually Do
This is not a prescription — India Herald is a newsroom, not a clinic — but the evidence-based consensus from the WHO, ICMR, and the Indian Medical Association is clear on three points that every household should internalise before the monsoon deepens:
First, no antibiotic without a prescription from a qualified physician. Ever. The convenience is not worth the resistance you are breeding — for yourself and for everyone. Second, paracetamol is not harmless: the safe ceiling is 4 grams per day for a healthy adult, and liver damage from chronic overuse is real, documented, and often irreversible by the time symptoms appear. Third, a cough lasting more than two weeks, a fever that returns after subsiding, or diarrhoea persisting beyond 48 hours are clinical signals, not pharmacy-counter problems — they warrant a doctor, not a repeat purchase.
The man in Ameerpet got his blue syrup. His cough, if he is lucky, will clear in a week. If he is unlucky, the syrup will suppress a symptom that was trying to tell him something his body already knew and his pharmacy never asked.
That silence at the counter — the question not asked, the prescription not required, the record not kept — is the sound of a system that has decided convenience is worth more than care. The question India has not answered, and the monsoon will ask again, is: how many ICU beds is that silence worth?
Reported and written with AI assistance under India Herald's editorial standards; a human editor governs publication.
This report is journalistic, not medical advice; consult a qualified professional.
More from India Herald
Key Takeaways
- India's self-medication prevalence in urban areas ranges from 50–73%, per Indian Journal of Pharmacology studies, making the pharmacy counter the de facto first point of care for a majority.
- Nearly 46% of antibiotics dispensed across five metro-city pharmacies were sold without prescriptions, according to an Indian Medical Association survey — directly fuelling antimicrobial resistance.
- Drug-induced liver injury from unsupervised paracetamol use accounts for roughly 10% of acute liver failure cases at major Indian tertiary hospitals, per the Journal of Clinical and Experimental Hepatology.
- India is the world's largest consumer of antibiotics (Lancet Infectious Diseases), and ICMR surveillance shows resistance rates exceeding 70% for some first-line antibiotics in hospital isolates.
- The Drugs and Cosmetics (Amendment) Bill discussions remain pending through 2026, with comprehensive prescription-enforcement and online-pharmacy regulation caught between industry lobbying and implementation inertia.
By the Numbers
- ₹12,000 crore — estimated value of India's OTC pharmaceutical market in 2024–25 (Indian Pharmaceutical Alliance / IQVIA estimates)
- 50–73% — self-medication prevalence range in urban India (Indian Journal of Pharmacology)
- 46% — share of antibiotics sold without prescriptions across five metro cities (Indian Medical Association survey)
- ~10% — share of acute liver failure cases at major centres attributed to drug-induced liver injury, often paracetamol-related (Journal of Clinical and Experimental Hepatology)
- 70%+ — resistance rates for some first-line antibiotics in Indian hospital isolates (ICMR annual surveillance)
- 1:1,000 — India's overall doctor-to-population ratio, masking severe urban-rural disparity (National Health Profile 2023, CBHI)
click and follow Indiaherald WhatsApp channel